Unlike other MIGS which create artificial flow, iTrack™ is a stent-free, tissue-sparing procedure that treats 360° of the conventional outflow pathway to re-establish natural aqueous flow. It combines a process of microcatheterisation and viscodilation to address all potential points of blockage in the conventional outflow pathway, including; the trabecular meshwork, Schlemm’s canal and the collector channels, removing the guesswork inherent in stent-based MIGS procedures.
The iTrack™ procedure avoids removing or tearing trabecular meshwork tissue, in particular, preserving the conjunctiva and angle for any future procedures. Artificial flow created by stent-based MIGS procedures may result in excessive damage to the corneal endothelium. Specifically, it has been suggested that altering aqueous currents to one point of exit may damage the corneal endothelium, leading to Endothelial Cell Loss (ECL). By targeting the entire circumference of the conventional outflow pathway, iTrack™ may limit the risk of ECL.
A narrow or collapsed Schlemm’s canal correlates with a decrease in the outflow facility by as much as 50% in POAG eyes. Separating the compressed trabecular plates of the trabecular meshwork, iTrack™ mechanically breaks adhesions within Schlemm’s canal and dilates the canal by up to 2-3 times via a process of viscodilation.Up to 90% of collector channels may be blocked by herniated trabecular meshwork in POAG eyes. iTrack™ reduces herniations in the collector channels via a process of pressurised viscodilation.
FURTHER INFORMATION:
